Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Labeling for Pediatric MRI

Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug Administration (FDA) approval for an extension to include magnetic resonance imaging (MRI) of the central nervous system (CNS) in pediatric patients younger than 2 years of age (including term neonates). The agent may now be used in this patient population to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine and associated tissues.

Use of Eovist in Pediatric Patients: Pearls and Pitfalls - ScienceDirect

Considerations in the Selection of a New Gadolinium-Based Contrast Agent • APPLIED RADIOLOGY

MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice

FDA Expands Labeling of MultiHance for Magnetic Resonance Angiography

Bracco Launches CT Exprès 3-D Contrast Media Delivery System at RSNA 2016

Bracco Diagnostics Unveils Contrast Media and Device Offerings at RSNA 2019 - RSNA 2019 - mobile.

X-ray-computed tomography contrast agents. - Abstract - Europe PMC

Gadolinium What Is Gadolinium & What Is It Used for in MRIs?

Bracco's MultiHance to Show Improved MR Visualization

Contrast-enhanced Magnetic Resonance Imaging in Pediatric Patients: Review and Recommendations for Current Practice - Ravi Bhargava, Gabriele Hahn, Wolfgang Hirsch, Myung-Joon Kim, Hans-Joachim Mentzel, Øystein E. Olsen, Eira Stokland, Fabio Triulzi, Elida

Pull linear MRI contrast from market, European group says

Use of Eovist in Pediatric Patients: Pearls and Pitfalls - ScienceDirect